Back to top

Image: Bigstock

Lilly's Crohn's Disease Candidate Meets Phase II Study Goals

Read MoreHide Full Article

Eli Lilly and Company (LLY - Free Report) announced that a phase II study evaluating its pipeline candidate mirikizumab in patients with moderately-to-severely active Crohn's disease (“CD”) met the primary and secondary endpoints.

Data from the phase II SERENITY study showed that treatment with mirikizumab led to significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo. The data were presented at Digestive Disease Week medical conference in San Diego, CA. Lilly plans to begin phase III studies on mirikizumab in Crohn's disease later this year. Mirikizumab is already being evaluated in phase III studies in other immune diseases, psoriasis and ulcerative colitis.

Some popular drugs approved to treat Crohn's disease are AbbVie’s (ABBV - Free Report) Humira and UCB’s Cimzia, among others while several others like AbbVie’s newly approved psoriasis drug Skyrizi (risankizumab), Theravance Biopharma, Inc.’s (TBPH - Free Report) JAK inhibitor TD-1473 Galapagos and Gilead’s (GILD - Free Report) filgotinib and RedHill Biopharma Ltd  RHB-104 are in late-stage studies for CD.

Immunology is a key therapeutic area for Lilly and its portfolio includes popular drug Taltz, which is marketed for the treatment of psoriasis and psoriatic arthritis. Meanwhile, regulatory applications seeking approval of Taltz for axial spondyloarthritis are also under review with the FDA. Lilly is also seeking to expand its immunology pipeline. In the first quarter, Lilly announced global licensing and research collaboration with two companies, ImmuNext, Inc. and Avidity Biosciences, Inc to make new medicines in immunology and autoimmune diseases.

Lilly’s shares have risen 0.7% this year so far against the industry’s decline of 1.2%.

 

Lilly currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>